IDXX Stock Recent News

While the top- and bottom-line numbers for Idexx (IDXX) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Idexx Laboratories (IDXX) came out with quarterly earnings of $2.32 per share, beating the Zacks Consensus Estimate of $2.12 per share. This compares to earnings of $2.05 per share a year ago.

IDEXX Laboratories (IDXX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Investors interested in stocks from the Medical - Instruments sector have probably already heard of IQVIA Holdings (IQV) and Idexx Laboratories (IDXX). But which of these two companies is the best option for those looking for undervalued stocks?

Evaluate the expected performance of Idexx (IDXX) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Investors continue to be optimistic about IDEXX (IDXX), backed by the strength of the CAG Diagnostics business.

Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Strength in CAG Diagnostics and Water businesses are likely to have boosted IDEXX Laboratories' (IDXX) revenues in Q4.

IDEXX's (IDXX) Fecal Dx antigen testing detects the most prevalent and clinically relevant intestinal parasites in dogs and cats.